X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
mutation (10) 10
cancer (8) 8
humans (7) 7
tumors (7) 7
genomes (6) 6
analysis (5) 5
genetic aspects (5) 5
multidisciplinary sciences (5) 5
mutations (5) 5
article (4) 4
b-cell lymphoma (4) 4
deoxyribonucleic acid--dna (4) 4
evolution (4) 4
female (4) 4
genomics (4) 4
heterogeneity (4) 4
lymphocytes b (4) 4
cell biology (3) 3
clonal evolution (3) 3
deactivation (3) 3
development and progression (3) 3
drug resistance, neoplasm - genetics (3) 3
gene expression (3) 3
gene sequencing (3) 3
genes (3) 3
genetics & heredity (3) 3
health aspects (3) 3
inactivation (3) 3
lymphoma (3) 3
metastasis (3) 3
patients (3) 3
research (3) 3
science (3) 3
signatures (3) 3
whole exome sequencing (3) 3
adult (2) 2
aged (2) 2
alterations (2) 2
blood (2) 2
breast-cancer (2) 2
cell cycle (2) 2
chromosomes (2) 2
chronic lymphatic leukemia (2) 2
comprehensive molecular portraits (2) 2
computer simulation (2) 2
copy number (2) 2
copy-number alteration (2) 2
disease progression (2) 2
dna methylation (2) 2
drug resistance, neoplasm - drug effects (2) 2
gene expression regulation, neoplastic - drug effects (2) 2
gene mutations (2) 2
genes, neoplasm (2) 2
genetic drift (2) 2
genomic characterization (2) 2
landscape (2) 2
lesions (2) 2
leukemia (2) 2
loss of heterozygosity (2) 2
lung-cancer (2) 2
male (2) 2
metastases (2) 2
middle aged (2) 2
mutation - genetics (2) 2
mutational landscape (2) 2
neoplasm metastasis (2) 2
nucleotide sequence (2) 2
oncology (2) 2
oncology, experimental (2) 2
resistance (2) 2
rna (2) 2
sequencing data (2) 2
target acquisition (2) 2
therapy (2) 2
transcription (2) 2
transcriptome - genetics (2) 2
treatment outcome (2) 2
tumor proteins (2) 2
acquired-resistance (1) 1
adenocarcinoma (1) 1
adults (1) 1
agammaglobulinaemia tyrosine kinase (1) 1
aged, 80 and over (1) 1
aging (1) 1
allelic imbalance (1) 1
animals (1) 1
antecedents (1) 1
antibodies, monoclonal - immunology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antigen presentation (1) 1
antigen presentation - drug effects (1) 1
antigen presentation - genetics (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis (1) 1
automobile drivers (1) 1
autopsies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Tarabichi, Maxime and Tarabichi, Maxime and Martincorena, Iñigo and Gerstung, Moritz and Gerstung, Moritz and Leroi, Armand M and Markowetz, Florian and Markowetz, Florian and Dentro, Stefan C and Leshchiner, Ignaty and Spellman, Paul T and Morris, Quaid D and Jolly, Clemency and Lingjærde, Ole Christian and Haase, Kerstin and Wedge, David C and Wintersinger, Jeff and Deshwar, Amit G and Van Loo, Peter and Yu, Kaixian and Gonzalez, Santiago and Rubanova, Yulia and Macintyre, Geoff and Adams, David J and Anur, Pavana and Beroukhim, Rameen and Boutros, Paul C and Bowtell, David D and Campbell, Peter J and Cao, Shaolong and Christie, Elizabeth L and Cmero, Marek and Cun, Yupeng and Dawson, Kevin J and Demeulemeester, Jonas and Donmez, Nilgun and Drews, Ruben M and Eils, Roland and Fan, Yu and Fittall, Matthew and Garsed, Dale W and Getz, Gad and Ha, Gavin and Imielinski, Marcin and Jerman, Lara and Ji, Yuan and Kleinheinz, Kortine and Lee, Juhee and Lee-Six, Henry and Livitz, Dimitri G and Malikic, Salem and Mitchell, Thomas J and Mustonen, Ville and Oesper, Layla and Peifer, Martin and Peto, Myron and Raphael, Benjamin J and Rosebrock, Daniel and Sahinalp, S. Cenk and Salcedo, Adriana and Schlesner, Matthias and Schumacher, Steven and Sengupta, Subhajit and Shi, Ruian and Shin, Seung Jun and Stein, Lincoln D and Vázquez-García, Ignacio and Vembu, Shankar and Wheeler, David A and Yang, Tsun-Po and Yao, Xiaotong and Yuan, Ke and Zhu, Hongtu and Wang, Wenyi and Morris, Quaid D and Spellman, Paul T and Wedge, David C and Van Loo, Peter and Lingjærde, Ole Christian and PCAWG Evolution Heterogeneity and PCAWG Evolution and Heterogeneity Working Group and The PCAWG Evolution and Heterogeneity Working Group
Nature Genetics, ISSN 1061-4036, 12/2018, Volume 50, Issue 12, pp. 1630 - 1633
According to this traditional model, the selective advantage is conferred by a small set of driver mutations, but as the subclones that bear them successively... 
PATTERNS | CLONAL EVOLUTION | CANCER | GENETICS & HEREDITY | Research | Neutral evolution | Oncology, Experimental | Cancer | Genetic drift | Medical research | Computer simulation | Neutrality | Genomes | Gene sequencing | Genetic variance | Simulation | Cell death | Frequency distribution | Drift | Mutation | Charitable foundations | Tumors | Apoptosis
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2018, Volume 24, Issue 5, pp. 679 - 690
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1324 - 13
Journal Article
Nature Genetics, ISSN 1061-4036, 10/2017, Volume 49, Issue 10, pp. 1476 - 1486
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1136 - 11
Journal Article
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 2185 - 12
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents. To define the evolutionary dynamics induced by... 
B-CELL LYMPHOMA | TUMOR-MICROENVIRONMENT | MULTIDISCIPLINARY SCIENCES | INITIAL THERAPY | RESISTANCE | CLONAL EVOLUTION | MUTATIONS | SEQUENCING DATA | SINGLE-ARM | GENOME | PROGRESSION | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Clonal Evolution - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Rituximab - therapeutic use | Phospholipase C gamma - genetics | Aged, 80 and over | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Molecular Targeted Therapy - methods | Pyrazoles - pharmacology | Signal Transduction | Clonal Evolution - drug effects | Down-Regulation | Treatment Outcome | Pyrimidines - pharmacology | Disease Progression | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Whole Exome Sequencing | Rituximab - pharmacology | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mutation | Longitudinal Studies | Drug Resistance, Neoplasm - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Lymphocyte receptors | Therapy | Energy metabolism | Chronic lymphatic leukemia | Transcription | Leukemia | Lymphatic leukemia | Metabolism | Drug resistance | Gene expression | Bruton's tyrosine kinase | Signaling | Lymphocytes B | Immunotherapy | Cell cycle | Evolution | Cancer | Index Medicus
Journal Article